Phase 3 Readout~month

Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S

Indication
Cough; Refractory Chronic Cough

Other upcoming events for GSK

Phase 3 ReadoutPhase 3 Topline: A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S — GSK Phase 3 Readout | BioSniper